|
Endo Pushes FDA for Stricter Generic Opana Requirements
Endo Pharmaceuticals is petitioning the FDA to require that generic-makers referencing its crush-resistant pain drug Opana ER CRF demonstrate their products are similarly crush-resistant.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives